Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Sanofi (NASDAQ:SNY – Get Free Report) was the target of unusually large options trading on Monday. Traders acquired 2,013 put options on the company. This is an increase of approximately 68% compared ...

Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing ...

(RTTNews) - Sanofi's Consumer Healthcare division ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...